The recent COVID-19 pandemic and resulting breakdown of community-based services for people with dementia and their caregivers emphasized the importance
WHO today accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms.